Strategy for the production of human monoclonal antibodies using in vitro activated B cells.
An up-to-date strategy to optimally produce human monoclonal antibodies by primary in vitro immunization or by secondary in vivo stimulation of immunized donors is discussed in detail. The effect of a lysosomotropic amino acid dipeptide on the B cell suppression by lysosome-rich cytolytic cells and the subsequent Epstein-Barr virus transformation of immune B lymphocytes is explained. The described strategy allows a routine production of human hybridomas, derived from peripheral blood lymphocytes and exhibiting a productivity in the range of 20-50 micrograms Ig/24 h per 10(6) cells. Furthermore, the possibilities to modulate antibody isotype and affinity by molecular biological methods is reviewed.
Borrebaeck
C A
CA
Department of Biotechnology, University of Lund, Sweden.
D000911:Antibodies, Monoclonal / Q000096:biosynthesis*; D000915:Antibody Affinity; D001402:B-Lymphocytes / Q000276:immunology*; D001685:Biological Factors / Q000494:pharmacology; D002478:Cells, Cultured; D016207:Cytokines; D006801:Humans; D007132:Immunoglobulin Isotypes; D066298:In Vitro Techniques; D008213:Lymphocyte Activation
D000911:Antibodies, Monoclonal; D001685:Biological Factors; D016207:Cytokines; D007132:Immunoglobulin Isotypes